CROS NT Ltd Announces Appointment of Andrew MacGarvey as CEO

LONDON, Dec. 12, 2013 /PRNewswire-iReach/ -- As part of the CROS NT Group global strategy, the company today announced the appointment of Andrew MacGarvey to the role of Chief Executive Officer and President from 1st January 2014. The move sees Paolo Morelli move into the role of Chairman for CROS NT allowing him to dedicate more time to PMH the holding company which oversees other life science businesses including ARITHMOS, its technology arm.

Paolo Morelli said, 'I am pleased to appoint Andrew as CEO of CROS NT, it is the culmination of a two-year plan. Andrew has overseen our expansion into the UK and USA and his combination of commercial and operational knowledge, alongside his passion for customer service, makes him the right candidate to take CROS NT forward. Andrew understands that we are a people business and I am confident he will continue to grow the company in a sustainable way. He has built a great team to support him and I look forward to watching them in the next phase of the CROS NT story.'

Morelli will devote more time to PMH, 'There are some great things happening within PMH and the time is right for me to dedicate more time to this project. I intend to work closely with ARITHMOS next year; the life sciences technology space has always excited me. Within ARITHMOS, we have the right portfolio of technologies and I want to make sure we are connecting with the market and getting these products to our customers'.

Andrew MacGarvey said 'It was a privilege to be asked to take on the role of CEO of CROS NT and I was delighted to accept the position. Paolo has built a company that reflects his philosophy. Every member of the team is highly valued, as are each and every one of our customers. My job is to continue to build the business, while ensuring we protect the unique way we work, and I am looking forward to the challenge. We are seeing growing demand for our offering, specialist statistical and data services delivered through a global organisation. Following our activities this year we are now able to deliver these services across the pharmaceutical, biotechnology and medical device sectors.'

MacGarvey brings over 15 years' experience in the sector to the role. He has worked at a number of CROs in senior positions covering both the commercial and operational areas. He has lived and worked in both the USA and the UK giving him an international perspective on the sector.

About CROS NT

In its 21st year, CROS NT is a global Contract Research Organization (CRO) specialized in clinical data services. With over 800 studies completed in a variety of therapeutic areas and indications, CROS NT has remained focused on biometrics including statistical consultancy, programming and analysis, clinical data management, medical writing, pharmacovigilance and life science technology solutions. We collect, integrate and analyze data from various sources and uses processes and technology to ensure excellent project governance, reporting and traceability. 

Media Contact: Mary Wieder, CROS NT Ltd, +44 (0)1908 488822, mary.wieder@crosnt.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE CROS NT